InvestorsHub Logo
Followers 187
Posts 37534
Boards Moderated 3
Alias Born 09/24/2000

Re: manfromjax post# 91

Friday, 05/24/2024 9:08:48 AM

Friday, May 24, 2024 9:08:48 AM

Post# of 342
ALLR 8k out
this is why I thought it would be going much higher

Item 2.02 Results of Operations and Financial Condition.



On May 14, 2024, the Company issued a press release announcing its financial results for its fiscal quarter ended March 31, 2024 (the “Press Release”). A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.



Item 8.01 Other Events.



The Press Release discussed that the Company concluded its Phase 2 clinical trial of stenoparib early due to clear clinical benefits observed, including tumor shrinkage and long-term disease stability, in heavily pre-treated ovarian cancer patients. Using the Company’s DRP® companion diagnostic to pre-screen patients, the trial targeted those most likely to benefit. The promising results have provided sufficient proof of concept, prompting the Company to halt enrollment with the purpose of preparing a follow-on trial with FDA regulatory intent.

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.